



## Ethno-pharmaceuticals Fighting UTI-Resistant Bacteria: Synergistic Potential Exploration

Pragnya Paramita Acharya\* and Soumya Jal

School of Paramedics and Allied Health Sciences, Centurion University of Technology and Management, Odisha, India

\*Correspondence E-mail: [pragnyaacharya8@gmail.com](mailto:pragnyaacharya8@gmail.com)

### Abstract

Urinary tract infections (UTIs) are a pressing global health concern, exacerbated by the rise of antibiotic-resistant bacterial strains. Bioprospecting, involving the exploration of natural resources for therapeutic potential, offers a promising approach to tackling this challenge. Ethnopharmaceuticals, traditional medicinal practices and remedies from indigenous communities, present a valuable source for discovering novel bioactive compounds. This review comprehensively evaluates the bioprospecting of ethnopharmaceuticals and their synergistic potential against antibiotic-resistant UTIs. Drawing from existing literature, we analyze a diverse range of ethnopharmaceuticals, elucidating their mechanisms of action and experimental evidence supporting synergistic interactions. Ethno-pharmaceuticals encompass various plant-based extracts, traditional herbal remedies, and indigenous healing practices utilized across generations to manage infections. We examine the scientific evidence supporting their efficacy in treating UTIs, clarifying their bioactive components and modes of action. Integration of traditional knowledge with modern scientific methodologies is crucial to addressing contemporary health challenges. By harnessing the synergistic potential of ethnopharmaceuticals, we can develop alternative therapies for UTIs, offering hope for improved treatment outcomes amidst antibiotic resistance.


**Keywords:** Antibiotic resistance, Bacterial infections, Bioactive compounds, Bioprospecting, Ethnopharmaceuticals, Synergistic potential, UTI-resistant bacteria

### Introduction

Urinary Tract Infections (UTIs), primarily caused by bacterial pathogens, remain among the most commonly diagnosed infections globally. The severity of UTIs ranges from uncomplicated, which are primarily community-acquired, to complicated, which are often nosocomial or healthcare-associated. These infections not only result in significant patient morbidity but also cause a massive economic burden due to lost workdays, medical consultations, and treatments (Foxman, 2014). With the emergence of antibiotic resistance, the situation becomes even more complex and alarming.

#### *Urinary Tract Infections (UTIs) and Antibiotic Resistance*

UTIs are predominantly caused by uropathogenic *Escherichia coli* (UPEC), accounting for up to 80% of cases. Other bacterial culprits include *Klebsiella pneumoniae*, *Enterococcus faecalis*, and *Staphylococcus saprophyticus* (Flores-Mireles *et al.*, 2015). While antibiotics have been the cornerstone of UTI treatments, over-reliance and misuse have led to the rise of antibiotic-resistant strains (Figure 1).



**Figure:1.** Understanding the interplay between microbial biofilms, antibiotic resistance mechanisms, and host immune responses for effective treatment strategies.

Antibiotic resistance happens when bacteria evolve mechanisms to negate the killing effect of antibiotics. This phenomenon is a direct consequence of the exposure of bacteria to sub-lethal doses of antibiotics, either due to the misuse of prescribed antibiotics by patients, the use of antibiotics in livestock, or improper disposal, leading to environmental contamination (Martinez, 2009, Manyi-Loh *et al.*, 2018). For UTIs, this resistance is particularly concerning. Fluoroquinolones, a class of antibiotics frequently prescribed for UTIs, are now facing increasing resistance rates. In some regions, resistance to ciprofloxacin, a commonly used fluoroquinolone, has reached alarming levels, making it an ineffective treatment option (Gupta *et al.*, 2011). This resistance has led to the return of older antibiotics, such as nitrofurantoin and Fosfomycin, to the forefront of UTI treatment. Yet, these too aren't devoid of resistance issues (Gardiner *et al.*, 2019).

Extended Spectrum Beta-Lactamase (ESBL)-producing bacteria, which show resistance to a wide range of antibiotics, including penicillin and cephalosporins, have been increasingly identified in community-acquired UTIs. This resistance severely limits the therapeutic options available for outpatients and may necessitate the use of intravenous antibiotics like carbapenems (Tandogdu & Wagenlehner, 2016, Shaikh *et al.*, 2015).

The gravity of the situation becomes evident when considering the prospect of the "post-antibiotic" era, where common infections like UTIs could become untreatable. The World Health Organization has acknowledged this as one of the most significant global challenges in the 21st century (World Health Organization, 2014).

#### *Role of Bioprospecting in Addressing Antibiotic Resistance*

Bioprospecting, the process of discovery and commercial application of new products based on biological resources, has long been an avenue for the identification of potential therapeutic agents. Historically, nature has been a prolific provider of medicinal compounds, with many of our current antibiotics, such as penicillin, having natural origins (Watve *et al.*, 2001; Cushnie *et al.*, 2020).

In the current context of increasing antibiotic resistance, bioprospecting is particularly relevant. As the development of new synthetic antibiotics slows and the efficacy of existing ones diminishes, there is an urgent need to search for alternative antimicrobial agents. Nature, with its vast biodiversity, offers a rich reservoir of chemical compounds with potential antimicrobial properties yet to be explored (Newman & Cragg, 2016, Gupta & Sharma, 2022).

Several benefits underscore the importance of bioprospecting in addressing antibiotic resistance:

**Diversity of Compounds:** Natural environments harbor a plethora of organisms that produce unique secondary metabolites as a defense mechanism. These compounds, refined through millions of years of evolution, often have specific targets and mechanisms of action, distinct from current synthetic antibiotics (Clardy *et al.*, 2006).

**Unique Mechanisms of Action:** Natural products may target bacterial processes or structures not targeted by current antibiotics, potentially bypassing existing resistance mechanisms. For instance, certain marine organisms produce compounds that disrupt bacterial biofilm formation, a major contributor to antibiotic resistance (Skindersoe *et al.*, 2008, Asma *et al.*, 2022).

**Synergistic Interactions:** Nature often uses combinations of compounds to exert its effects. Bioprospecting can identify these combinations, which may act synergistically, enhancing antimicrobial activity or reducing potential side effects (González-Lamothe *et al.*, 2009, Vaou *et al.*, 2022, Basavegowda and Baek, 2022).

**Reduced Development Time:** By identifying compounds with established antimicrobial activity in nature, the time required for initial screening and optimization may be reduced, potentially accelerating the drug development process (Butler *et al.*, 2014).

Although bioprospecting holds great promise, challenges such as ethical considerations regarding access and benefit-sharing, sustainable harvesting, and the intricate drug development process remain. Nevertheless, integrating modern technologies like genomics and metabolomics with traditional bioprospecting can enhance the discovery of novel antimicrobial agents, providing hope in combating antibiotic resistance (Millum, 2010, Muteeb *et al.*, 2024).

## Ethno-Pharmaceuticals: A Source of Bioactive Compounds

### Definition and Scope of Ethno-Pharmaceuticals

Ethno-pharmaceuticals, as the term suggests, is an interdisciplinary domain that intersects ethnobotany and pharmacology. It is chiefly concerned with the scientific study of indigenous medicines derived from plants, animals, and minerals, which are used for healing purposes by local or indigenous communities (Pirintsos *et al.*, 2022; Elisabetsky & Wannmacher, 1993). This realm offers a detailed insight into how traditional knowledge, often passed down through generations, harnesses the therapeutic potential of natural resources.

The diversity of ethno-pharmaceuticals derived from traditional medicinal practices worldwide, including plant-based extracts, herbal remedies, and indigenous healing practices, By illustrating the wide array of ethno-pharmaceuticals, the figure emphasizes their importance as reservoirs of bioactive compounds with therapeutic potential. This visual aid serves to underscore the significance of exploring ethno-pharmaceuticals in drug discovery and development processes (Table 1).

**Table:1** Examples of ethno-pharmaceuticals along with their associated bioactive compounds and their respective pharmacological properties. Each entry elaborates on the specific bioactive compounds found in the ethno-pharmaceutical and their known therapeutic effects, highlighting the diverse range of bioactivities exhibited by these natural products.

Ethno-Pharmaceutical	Bioactive Compounds
Neem ( <i>Azadirachta indica</i> )	Azadirachtin, Nimbidin - Insecticidal and anti-inflammatory properties.
Ginseng	Ginsenosides - Adaptogenic and immunomodulatory effects.
Turmeric ( <i>Curcuma longa</i> )	Curcumin - Anti-inflammatory, antioxidant, and anticancer properties.
Aloe Vera	Aloin, Aloe-emodin - Wound healing and anti-inflammatory effects.
Ginger ( <i>Zingiber officinale</i> )	Gingerol, Shogaol - Antiemetic, anti-inflammatory, and antioxidant effects.
Tea Tree Oil	Terpinen-4-ol - Antimicrobial and anti-inflammatory properties.
Ginkgo Biloba	Ginkgolides, Bilobalide - Neuroprotective and vasodilatory effects.
Garlic ( <i>Allium sativum</i> )	Allicin, Ajoene - Antibacterial, antifungal, and cardioprotective effects.
Echinacea	Echinacoside, Cichoric acid - Immunostimulatory and anti-inflammatory effects.
St. John's Wort	Hypericin, Hyperforin - Antidepressant and antiviral properties.

## Diversity of Ethno-Pharmaceutical Remedies

Ethnopharmaceuticals are a reflection of the intricate relationship between indigenous communities and their environment. Spanning across continents and cultures, traditional medicinal systems have identified an array of remedies, showcasing an astounding diversity in both the sources of these remedies and their applications.

*Plant-based Remedies:* Plants have always been a primary source for ethnopharmaceuticals. It's estimated that about 50,000 to 70,000 plant species are used for medicinal purposes worldwide (Schippmann *et al.*, 2002; Chaachouay and Zidane, 2024). Whether it's the bark, leaves, roots, flowers, or seeds, various parts of these plants serve therapeutic purposes. Prominent examples include the use of willow bark (from which aspirin was derived) for pain relief and Cinchona tree bark for quinine, an early treatment for malaria (Newman & Cragg, 2012; Wood, 2015; Chaachouay and Zidane, 2024; Ralte *et al.*, 2024).

*Animal-based Remedies:* Traditional medicines frequently incorporate substances derived from animals. For example, the venom of certain snakes has been used in traditional Chinese medicine, while the secretion of the Amazonian tree frog is employed by indigenous South American tribes for its purported healing and spiritual properties (Alves & Rosa, 2007; Liu *et al.*, 2019).

*Mineral and Metal-based Remedies:* In systems like Ayurveda and Traditional Chinese Medicine, specific metals, minerals, and gemstones are ascribed therapeutic properties. However, the use of metals, especially heavy metals, requires careful scrutiny due to potential toxicity (Saper *et al.*, 2004).

*Fermented Preparations:* Many traditional cultures harness fermentation processes, which can enhance the therapeutic potential or reduce the toxicity of certain remedies. Fermented soy products, commonly used in East Asia, are good examples and believed to have various health benefits (Chung *et al.*, 2014; Siddiqui *et al.*, 2023).

*Combination Therapies:* Traditional remedies often involve mixtures of multiple ingredients. This practice is based on the belief that certain combinations can produce a synergistic effect, enhancing therapeutic potential and, in some cases, mitigating side effects (Williamson, 2001).

The wide-ranging diversity of ethno-pharmaceutical remedies underlines the richness of traditional knowledge. However, while these traditions offer a treasure trove of potential therapeutic agents, it's crucial to approach them with respect for indigenous rights and an emphasis on scientific validation to ensure safety and efficacy.

## Bioactive Compounds Found in Ethno-Pharmaceuticals

Ethno-pharmaceuticals, derived predominantly from plants, animals, and minerals, are replete with bioactive compounds that underlie their therapeutic properties. These bioactive constituents often have intricate structures and unique modes of action, making them invaluable for drug discovery and development. A deeper understanding of these compounds can provide insights into their pharmacological effects and therapeutic potential (Figure 2).

*Alkaloids:* These are nitrogen-containing organic compounds that often have pronounced physiological effects on humans. Alkaloids such as quinine from *Cinchona* bark have been historically important in treating malaria, while morphine from opium poppy is well-known for its analgesic effects (Cordell, 2013).


*Flavonoids:* Predominantly found in plants, flavonoids possess antioxidant, anti-inflammatory, and antiviral properties. Examples include quercetin and kaempferol, which are widespread in fruits, vegetables, and medicinal herbs (Kumar & Pandey, 2013).

*Terpenoids:* Comprising a large group of naturally occurring organic chemicals, terpenoids, or isoprenoids, often have strong aromas. They play key roles in traditional medicine, with examples like artemisinin from the *Artemisia annua* plant, which has transformed malaria treatment worldwide (Tu, 2011).

**Polyphenols:** These are a diverse group of compounds with antioxidant properties. Tannins, lignins, and curcumin are examples of polyphenols that have been explored for their potential health benefits, especially in the context of chronic diseases (Manach *et al.*, 2004).

**Saponins:** Found abundantly in several plants, saponins have a wide range of pharmacological effects, including immune-boosting and cholesterol-lowering properties (Oakenfull & Sidhu, 1990).

**Glycosides:** These are molecules wherein a sugar is bound to a non-carbohydrate moiety. Cardiac glycosides, like digoxin derived from the foxglove plant (*Digitalis purpurea*), are well-known for their role in treating heart disorders (Prassas & Diamandis, 2008).



**Figure 2:** Synergistic approaches reverse antibiotic resistance, enhancing effectiveness. Explore bioactive compounds, DNA replication, energy synthesis, toxins, and more for comprehensive understanding and efficient analysis.

### Mechanisms of Action of Ethno-Pharmaceuticals

#### *Disruption of Bacterial Cell Walls*

The cell wall is an essential component of bacterial cells, providing rigidity and protecting the organism from its surroundings, especially osmotic stress. A variety of ethnopharmaceuticals have demonstrated the ability to interfere with the structure and integrity of bacterial cell walls, leading to the lysis and death of the microorganisms.

**Peptidoglycan Targeting:** The primary component of most bacterial cell walls is peptidoglycan, a robust polymer that gives the bacterial cell its strength. Several ethno-pharmaceutical compounds have shown the ability to target and disrupt the synthesis or structure of peptidoglycan (Galinier *et al.*, 2023). For instance, certain plant-derived compounds inhibit enzymes like transpeptidase, which is crucial for cross-linking the peptidoglycan layers, leading to weak cell walls and bacterial death (Wright, 2005).

**Membrane Permeabilization:** Some bioactive compounds in ethnopharmaceuticals can integrate into bacterial membranes, increasing their permeability. This action disrupts the bacterial cell's internal osmotic balance, leading to an influx of extracellular compounds and eventual cell rupture. Essential oils, for instance, contain terpenes and terpenoids, which are known to permeabilize bacterial cell walls, causing the loss of essential ions and cellular contents (Vaou *et al.*, 2022).

**Lipopolysaccharide (LPS) Interference:** In Gram-negative bacteria, the outer layer is made of LPS, which offers additional protection and acts as an endotoxin. Compounds from certain medicinal plants

have been identified that can neutralize LPS or inhibit its synthesis, compromising the protective barrier of the bacterial cell and making it more susceptible to external threats (Hyldgaard *et al.*, 2012).

The promise of ethnopharmaceuticals in disrupting bacterial cell walls highlights the potential of these compounds as alternative or complementary therapies to conventional antibiotics, especially in the era of rising antibiotic resistance.

*Inhibition of Essential Enzymes:* Bacterial pathogens require several essential enzymes to carry out vital cellular processes, from DNA replication to protein synthesis. The inhibition of these enzymes disrupts the metabolic and reproductive cycles of the bacteria, leading to their demise. Ethnopharmaceuticals, rich in diverse bioactive compounds, have demonstrated the ability to target and inhibit such pivotal enzymes, making them potential tools in the fight against bacterial infections.

*DNA Gyrase and Topoisomerase IV Inhibition:* DNA gyrase and topoisomerase IV are enzymes that play key roles in bacterial DNA replication. Certain plant-derived compounds, such as alkaloids and flavonoids, have shown the potential to inhibit these enzymes, thereby preventing DNA replication and, subsequently, bacterial reproduction. Quercetin, a type of flavonoid found in various plants, for instance, has been recognized for its inhibitory effects on DNA gyrase (Plaper *et al.*, 2003).

*RNA Polymerase Inhibition:* RNA polymerase is another crucial enzyme responsible for transcribing DNA into RNA in bacteria. Ethno-pharmaceutical extracts from certain plants have demonstrated the capacity to impede this enzyme's function, leading to a disruption in protein synthesis. A classic example is the compound  $\alpha$ -terpineol from tea tree oil, which inhibits the RNA polymerase enzyme (Carson *et al.*, 2002).

*Enzymatic Wall Synthesis Inhibitors:* The synthesis of the bacterial cell wall requires various enzymes. Bioactive compounds from ethnopharmaceuticals can inhibit these enzymes, leading to defective cell walls (Eze *et al.*, 2023). For instance, baicalin, derived from the roots of *Scutellaria baicalensis*, inhibits the activity of penicillin-binding proteins involved in cell wall synthesis (Che *et al.*, 2016).

The capacity of ethno-pharmaceuticals to inhibit essential bacterial enzymes underscores their potential as complementary or alternative antimicrobial agents, especially in scenarios where traditional antibiotics fail due to resistance.

#### *Interference with Bacterial Quorum Sensing*

Quorum sensing (QS) is a sophisticated bacterial communication system that orchestrates the expression of specific genes based on population density. By sensing the concentration of signaling molecules, bacteria can regulate virulence, biofilm formation, and other behaviors that affect their survival and pathogenicity. The interference of this quorum sensing is an innovative therapeutic strategy, as it does not kill the bacteria directly but instead weakens their virulence. Ethnopharmaceuticals, due to their vast array of bioactive compounds, have shown potential for interfering with bacterial quorum sensing.

*Signal Molecule Inhibition:* One of the primary ways to interfere with QS is by inhibiting the production or reception of signal molecules. Compounds such as ajoene, found in garlic extracts, have demonstrated inhibitory effects on the production of autoinducer molecules, thus disrupting quorum sensing in bacterial populations (Jakobsen *et al.*, 2012; Naga *et al.*, 2023).

*Inhibition of QS Regulated Genes:* Certain plant-derived compounds can also disrupt QS by directly inhibiting the genes that are regulated by QS systems. For example, curcumin from turmeric has been shown to downregulate the expression of genes associated with virulence and biofilm formation in *Pseudomonas aeruginosa* (Rudrappa & Bais, 2008; Dai *et al.*, 2022; Shariati *et al.*, 2024).

*Degradation of Signal Molecules:* Some ethno-pharmaceutical compounds can degrade the signal molecules produced during QS, making them ineffective in relaying messages. Urocanic acid from tomato extracts is one such compound that has shown potential for degrading autoinducer molecules in bacterial cultures (Vattem *et al.*, 2007).

By interfering with quorum sensing, ethno-pharmaceuticals can attenuate bacterial pathogenicity, making them easier to combat with the host's immune system or other antimicrobial agents.

#### *Contrasting Mechanisms with Conventional Antibiotics*

Conventional antibiotics have been the bedrock of antimicrobial therapies for decades, playing a crucial role in reducing mortality rates associated with bacterial infections. These antibiotics typically work by targeting essential bacterial functions, leading to bacterial death or growth inhibition (Pancu *et al.*, 2021). However, the increasing cases of antibiotic resistance highlight the need for alternative strategies. Ethnopharmaceuticals provide such an avenue, but their mechanisms of action often contrast with those of conventional antibiotics. Understanding these differences can offer insights into the potential advantages of ethnopharmaceuticals and how they might be integrated into modern therapeutic regimens.

#### *Target Specificity:*

Conventional antibiotics usually work by targeting specific bacterial components or processes. For instance, penicillin disrupts cell wall synthesis by binding to bacterial enzymes responsible for peptidoglycan cross-linking (Tipper, 1985).

Ethnopharmaceuticals, on the other hand, often contain a myriad of compounds, each with a potential unique mechanism of action. This multi-targeted approach can be more difficult for bacteria to develop resistance against compared to the single-target action of many antibiotics.

#### *Resistance Development:*

Antibiotics are potent agents that exert strong selective pressure on bacterial populations, leading to the emergence of resistant strains. For example, the misuse of fluoroquinolones has been associated with the rise of resistant strains of *Staphylococcus aureus* and other pathogens (Hooper & Jacoby, 2016; Nasrollahian *et al.*, 2024).

Ethno-pharmaceuticals may exert a milder effect on bacteria, modulating their activity without necessarily killing them. This subtler approach may reduce the immediate selective pressure for resistance, although further research is needed in this area.

#### *Mode of Action:*

Antibiotics generally have well-defined modes of action, be it disruption of protein synthesis, as seen with tetracyclines, or interference with DNA replication, as with quinolones (Chopra & Roberts, 2001; Nasrollahian *et al.*, 2024).

Ethno-pharmaceuticals' modes of action can be more diverse, given the complex mixture of bioactive compounds they contain. They might work by modulating host immunity, directly attacking bacterial components, or interfering with bacterial signaling, as discussed in the previous sections.

#### *Synergistic Potential of Ethno-Pharmaceuticals*

##### *Concept of Synergy in Antimicrobial Activity*

The synergy concept in antimicrobial activity refers to the combined effect of two or more agents, which together produce a result greater than the sum of their individual effects. In the realm of ethnopharmaceuticals and traditional medicine, such synergistic effects are not uncommon, as many remedies consist of complex mixtures of different bioactive compounds that can act in concert against microbial pathogens.

##### *Synergy Definition:*

Synergy in antimicrobial therapy is typically identified when the combined effect of two agents is significantly greater than the sum of their individual effects. This phenomenon contrasts with an additive effect, where the combined action is simply the sum of the individual effects, and with

antagonism, where the combined effect is less than the individual effects (Eliopoulos & Moellering, 1996).

*Methods of Synergy Evaluation:*

Several laboratory methods are designed to assess synergism, including the checkerboard and time-kill assays. The fractional inhibitory concentration index (FICI) derived from these assays provides a quantitative measure of synergy, with FICI values less than 0.5 typically indicating synergism (Odds, 2003).

*Advantages of Synergistic Combinations:*

Synergistic combinations can enhance antimicrobial potency, potentially allowing for reduced dosages and, consequently, reduced side effects. Furthermore, they might broaden the antimicrobial spectrum, enabling effective treatment against a wider range of pathogens (Eliopoulos & Moellering, 1996).

Another critical aspect is the potential delay or prevention of resistance development. When two compounds act synergistically, a pathogen would need to simultaneously develop resistance mechanisms to both agents, a less likely scenario than resistance against a single agent (Wright, 2016).

*Historical and Cultural Context:*

Throughout history, many traditional medicine systems, such as Ayurveda and Traditional Chinese Medicine, have utilized combinations of plants and herbs, capitalizing on potential synergistic interactions. These combinations might have been empirically optimized over generations for their therapeutic efficacy (Williamson, 2001; Ibáñez *et al.*, 2023). Table-2.

**Table 2:** This table provides examples of combination therapies from Ancient Egyptian Medicine, Ayurveda, and Traditional Chinese Medicine, along with their respective primary symptoms, hierarchical structures, and scientific rationales for their effectiveness.

Traditional Medicine System	Example Formulation	Primary Symptom	Hierarchical Structure	Scientific Rationale
Ancient Egyptian Medicine	Ebers Papyrus recipes	Varied ailments	-----	Empirical observations
Ayurveda	Triphala	Digestive issues	-----	Synergistic properties
Ayurveda	Dashamoola	Pain management	-----	Synergistic properties
Traditional Chinese Medicine (TCM)	Yin Qiao San	Cold symptoms	King-minister-assistant-courier	Enhanced bioavailability
Traditional Chinese Medicine (TCM)	Xiao Yao San	Stress relief	King-minister-assistant-courier	Reduced toxicity

*Traditional Practices and Combination Therapies*

Traditional medicine systems have often emphasized a holistic approach to healthcare, addressing not just the ailment but the overall well-being of the patient. Many of these systems have utilized combination therapies, which incorporate multiple herbs or ingredients to achieve therapeutic outcomes. These combinations, whether driven by empirical observations or deeper philosophical or theoretical constructs, represent early recognitions of synergistic potentials in therapeutic applications. Historical records from various cultures illustrate the long-standing use of combination therapies. Ancient Egyptian papyri, like the Ebers Papyrus, contain recipes combining multiple plants and minerals for varied ailments (Bryan, 1930). Ayurveda, a traditional Indian medicine system, uses various polyherbal formulations like 'Triphala' and 'Dashamoola,' which are believed to have synergistic therapeutic properties (Pole, 2006; Ibáñez *et al.*, 2023).

**Discussion**

The potential of ethnopharmaceuticals in managing antibiotic-resistant urinary tract infections (UTIs) represents a significant shift towards integrating traditional knowledge with modern medicinal



practices. As the global incidence of antibiotic-resistant UTIs rises, the urgency to find viable alternatives to conventional antibiotics becomes paramount (Paul, 2018; Pothoven, 2023). This exploration into ethno-pharmaceuticals highlights the promising avenues for developing synergistic therapies that combine the efficacy of modern medicine with the holistic benefits of traditional remedies.

#### *Bioactive Potential of Ethnopharmaceuticals:*

The bioactive properties of ethnopharmaceuticals are diverse, encompassing antimicrobial, anti-inflammatory, and diuretic effects, which are crucial for the management of UTIs. For example, the phenolic compounds in cranberry extracts prevent the adhesion of bacteria such as *E. coli* to the lining of the urinary tract, effectively hindering the initial stage of infection (Kępińska-Pacelik & Biel., 2023). Additionally, the anti-inflammatory properties of turmeric, primarily due to curcumin, help reduce the symptoms of UTIs, such as pain and urgency, providing not only a preventative but also a therapeutic benefit (Ajaikumar *et al.*, 2023).

#### *Challenges in Application and Research:*

While the theoretical benefits of ethnopharmaceuticals are substantial, their practical application faces several challenges. The heterogeneity in preparation methods, dosages, and the bioactive profiles of these compounds poses significant hurdles in standardizing treatments that are both effective and reproducible. Furthermore, the interactions between these natural compounds and conventional antibiotics are not well-understood. Research in this area is fragmented, often limited by the complexity of natural product chemistry and the variability in clinical outcomes (Liu and Quinn 2019).

#### *Recent Advances and Future Research Directions:*

Recent studies in 2023 have begun to address these challenges through more structured experimental designs and advanced analytical techniques. Hammouti *et al.* (2023) have explored the synergistic effects of selected herbal extracts combined with reduced doses of antibiotics, finding that certain combinations can enhance the antibiotic effect while potentially reducing the likelihood of resistance development. This approach not only underscores the importance of synergy in ethno-pharmaceutical applications but also points towards a sustainable strategy in antibiotic stewardship.

#### *Regulatory and Ethical Considerations:*

As research progresses, the need for rigorous regulatory frameworks becomes evident. Ensuring the safety, efficacy, and quality of ethnopharmaceuticals through stringent regulatory guidelines is essential. Additionally, ethical considerations, particularly regarding the bioprospecting of indigenous knowledge, must be addressed. Ensuring that communities providing this knowledge benefit from its commercialization is a moral imperative that researchers and pharmaceutical companies need to uphold (Pirintsos *et al.*, 2022).

#### *Integration into Health Systems:*

For ethnopharmaceuticals to be effectively integrated into health systems, a multidisciplinary approach is required. This involves collaboration between ethnobotanists, pharmacologists, microbiologists, and healthcare practitioners (Pirintsos *et al.*, 2022). Educational programs aimed at both healthcare providers and patients can facilitate the acceptance and understanding of these alternative therapies, thereby promoting their use under clinically approved standards.

Future research in UTI treatment should prioritize interdisciplinary collaborations to expedite the discovery and application of bioactive compounds from traditional remedies. Advanced extraction techniques like mass spectrometry and NMR spectroscopy will provide deeper insights, while rigorous clinical trials and ethical bioprospecting are essential for integration into healthcare. Investigating combination therapies and innovative drug delivery systems will further enhance efficacy and sustainability against rising antibiotic resistance.

## Conclusion

The global challenge of antibiotic-resistant bacterial strains, notably in Urinary Tract Infections (UTIs), demands alternative therapeutic approaches. Ethno-pharmaceuticals, enriched by indigenous wisdom, offer diverse antimicrobial mechanisms, potentially enhancing efficacy and broadening action against resistant strains. Yet, integration into modern medicine requires addressing challenges like standardization, clinical trials, and regulatory hurdles, respecting indigenous knowledge and ethical considerations. The fusion of modern and traditional medicine heralds a patient-centric healthcare future. Embracing ethno-pharmaceutical insights can inspire innovative therapeutic strategies, fostering holistic approaches to combat antibiotic resistance, and redefine health and wellness.

## Acknowledgments

We would like to thank Centurian University, India for their support. Special thanks to Sushree Swagatika Subhadarsini for her kind assistance and meticulous efforts in helping correct the manuscript.

## Conflict of Interest

The authors declare no conflict of interest.

## References

- Alves, R. R., & Rosa, I. M. (2007). Biodiversity, traditional medicine and public health: where do they meet?. *Journal of ethnobiology and ethnomedicine*, 3, 1-9. <https://doi.org/10.1186/1746-4269-3-14>
- Amari, S., Karbab, A., Charef, N., Arrar, L., & Mubarak, M. S. (2023). Anti-urolithiatic, antibacterial, anti-inflammatory and analgesic effects of Erica arborea flowers and leaves hydromethanolic extracts: An ethnopharmacological study. *Saudi Journal of Biological Sciences*, 30(10). <https://doi.org/10.1016/j.sjbs.2023.103785>
- Asma, S. T., Imre, K., Morar, A., Imre, M., Acaroz, U., Shah, S. R. A., ... & Zhu, K. (2022). Natural strategies as potential weapons against bacterial biofilms. *Life*, 12(10), 1618. <https://doi.org/10.3390/life12101618>
- Basavegowda, N., & Baek, K. H. (2022). Combination strategies of different antimicrobials: an efficient and alternative tool for pathogen inactivation. *Biomedicines*, 10(9), 2219. <https://doi.org/10.3390/biomedicines10092219>
- Brayn, C. P., & Smith, G. E. (1930). The papyrus ebers, translated from the german version. *Letchworth, Herts: The Guardian City Press LTD.*
- Butler, M. S., Buss, A. D., & Evans-Illidge, E. (2014). Natural product libraries: Assembly, maintenance, and screening. *Planta Medica*, 80(14), 1161-1170. <https://doi.org/10.1055/s-0033-1360109>
- Carson, C. F., Mee, B. J., & Riley, T. V. (2002). Mechanism of action of Melaleuca alternifolia (tea tree) oil on Staphylococcus aureus determined by time-kill, lysis, leakage, and salt tolerance assays and electron microscopy. *Antimicrobial agents and chemotherapy*, 46(6), 1914-1920. <https://doi.org/10.1128/AAC.46.6.1914-1920.2002>
- Chaachouay, N., & Zidane, L. (2024). Plant-Derived Natural Products: A Source for Drug Discovery and Development. *Drugs and Drug Candidates*, 3(1), 184-207. <https://doi.org/10.3390/ddc3010011>
- Che, C. T., Wong, M. S., & Lam, C. W. (2016). Natural Products from Chinese Medicines with Potential Benefits to Bone Health. *Molecules (Basel, Switzerland)*, 21(3), 239. <https://doi.org/10.3390/molecules21030239>
- Chopra, I., & Roberts, M. (2001). Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. *Microbiology and molecular biology reviews*, 65(2), 232-260. <https://doi.org/10.1128/membr.65.2.232-260.2001>
- Chung, M. J., Park, J. K., Park, Y. I., Cho, S. Y., & Chi, H. Y. (2014). Anti-inflammatory effects of fermented soybean products in lipopolysaccharide-stimulated RAW 264.7 murine macrophages. *Journal of Medicinal Food*, 17(7), 763-770. <https://doi.org/10.1007/s12272-011-0418-3>
- Clardy, J., Fischbach, M. A., & Walsh, C. T. (2006). New antibiotics from bacterial natural products. *Nature biotechnology*, 24(12), 1541-1550. <https://doi.org/10.1038/nbt1266>
- Cordell, G. A. (2013). Fifty years of alkaloid biosynthesis in Phytochemistry. *Phytochemistry*, 91, 29-51. <https://doi.org/10.1016/j.phytochem.2012.05.012>

- Cushnie, T. T., Cushnie, B., Echeverría, J., Fowsantear, W., Thammawat, S., Dodgson, J. L., ... & Clow, S. M. (2020). Bioprospecting for antibacterial drugs: a multidisciplinary perspective on natural product source material, bioassay selection and avoidable pitfalls. *Pharmaceutical research*, 37(7), 125. <https://doi.org/10.1007/s11095-020-02849-1>.
- Dai, C., Lin, J., Li, H., Shen, Z., Wang, Y., Velkov, T., & Shen, J. (2022). The natural product curcumin as an antibacterial agent: Current achievements and problems. *Antioxidants*, 11(3), 459. <https://doi.org/10.3390/antiox11030459>.
- Eliopoulos, G. M., & Moellering, R. C. (1996). Antimicrobial combinations. In *Antibiotics in laboratory medicine* (pp. 330-396). Lippincott Williams & Wilkins.
- Elisabetsky, E., & Wannmacher, L. (1993). The status of ethnopharmacology in Brazil. *Journal of ethnopharmacology*, 38(2-3), 129-135. [https://doi.org/10.1016/0378-8741\(93\)90008-s](https://doi.org/10.1016/0378-8741(93)90008-s)
- Eze, C. N., Onyejiaka, C. K., Ihim, S. A., Ayoka, T. O., Aduba, C. C., Nwaiwu, O., & Onyeaka, H. (2023). Bioactive compounds by microalgae and potentials for the management of some human disease conditions. *AIMS microbiology*, 9(1), 55. <https://doi.org/10.3934/microbiol.2023004>
- Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nature reviews microbiology*, 13(5), 269-284. <https://doi.org/10.1038/nrmicro3432>
- Foxman, B. (2014). Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infectious Disease Clinics*, 28(1), 1-13. <https://doi.org/10.1016/j.idc.2013.09.003>
- Galiniér, A., Delan-Forino, C., Foulquier, E., Lakhali, H., & Pompeo, F. (2023). Recent advances in peptidoglycan synthesis and regulation in bacteria. *Biomolecules*, 13(5), 720. <https://doi.org/10.3390/biom13050720>
- Gardiner BJ, Stewardson AJ, Abbott IJ, Peleg AY. Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems. *Aust Prescr*. 2019 Feb;42(1):14-19. <https://doi.org/10.18773/austprescr.2019.002>
- González-Lamothe, R., Mitchell, G., Gattuso, M., Diarra, M. S., Malouin, F., & Bouarab, K. (2009). Plant antimicrobial agents and their effects on plant and human pathogens. *International journal of molecular sciences*, 10(8), 3400-3419. <https://doi.org/10.3390/ijms10083400>
- Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., ... & Soper, D. E. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clinical infectious diseases*, 52(5), e103-e120. <https://doi.org/10.1093/cid/ciq257>
- Gupta, R., & Sharma, S. (2022). Role of alternatives to antibiotics in mitigating the antimicrobial resistance crisis. *Indian Journal of Medical Research*, 156(3), 464-477. [https://doi.org/10.4103/ijmr.IJMR\\_3514\\_20](https://doi.org/10.4103/ijmr.IJMR_3514_20)
- Hammouti, Y., Elbouzidi, A., Taibi, M., Bellaouchi, R., Loukili, E. H., Bouhrim, M., ... & Addi, M. (2023). Screening of Phytochemical, Antimicrobial, and Antioxidant Properties of *Juncus acutus* from Northeastern Morocco. *Life*, 13(11), 2135. <https://doi.org/10.3390/life13112135>
- Hooper, D. C., & Jacoby, G. A. (2016). Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. *Cold Spring Harbor perspectives in medicine*, 6(9). <https://doi.org/10.1101/cshperspect.a025320>
- Hyltdgaard, M., Mygind, T., & Meyer, R. L. (2012). Essential oils in food preservation: mode of action, synergies, and interactions with food matrix components. *Frontiers in microbiology*, 3, 12. <https://doi.org/10.3389/fmicb.2012.00012>
- Ibáñez, B., Melero, A., Montoro, A., Merino-Torres, J. F., Soriano, J. M., & San Onofre, N. (2023). A Narrative Review of the Herbal Preparation of Ayurvedic, Traditional Chinese, and Kampō Medicines Applied as Radioprotectors. *Antioxidants*, 12(7), 1437. <https://doi.org/10.3390/antiox12071437>
- Jakobsen, T. H., Bragason, S. K., Phipps, R. K., & Christensen, L. D., Gennip M. V., Alhede, M., Skindersoe, M., Larsen, T.O., Høiby, N., Bjarnsholt, T., Givskov, M. (2012), Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of *Pseudomonas aeruginosa*. *Applied and Environmental Microbiology*. 78(7), 2410-2421 <https://doi.org/10.1128/AEM.05992-11>
- Kępińska-Pacelik, J., & Biel, W. (2023). Turmeric and Curcumin—Health-Promoting Properties in Humans versus Dogs. *International Journal of Molecular Sciences*, 24(19). <https://doi.org/10.3390/ijms241914561>
- Kumar, S., & Pandey, A. K. (2013). Chemistry and biological activities of flavonoids: an overview. *The scientific world journal*, 2013. <https://doi.org/10.1155/2013/162750>
- Kunnumakkara, A. B., Hegde, M., Parama, D., Girisa, S., Kumar, A., Daimary, U. D., ... & Aggarwal, B. B. (2023). Role of turmeric and curcumin in prevention and treatment of chronic diseases: Lessons learned from clinical trials. *ACS Pharmacology & Translational Science*, 6(4), 447-518. <https://doi.org/10.1021/acspsci.2c00012>

- Liu, M., & Quinn, R. J. (2019). Fragment-based screening with natural products for novel anti-parasitic disease drug discovery. *Expert Opinion on Drug Discovery*, 14(12), 1283-1295. <https://doi.org/10.1080/17460441.2019.1653849>
- Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. (2004). Polyphenols: food sources and bioavailability. *The American journal of clinical nutrition*, 79(5), 727-747. <https://doi.org/10.1093/ajcn/79.5.727>
- Manyi-Loh, C., Mamphweli, S., Meyer, E., & Okoh, A. (2018). Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. *Molecules*, 23(4), 795. <https://doi.org/10.3390/molecules23040795>
- Martinez, J. L. (2009). Environmental pollution by antibiotics and by antibiotic resistance determinants. *Environmental Pollution*, 157(11), 2893-2902. <https://doi.org/10.1016/j.envpol.2009.05.051>
- Millum, J. (2010). How should the benefits of bioprospecting be shared?. *Hastings Center Report*, 40(1), 24-33. <https://doi.org/10.1353/hcr.0.0227>
- Naga, N. G., El-Badan, D. E., Ghanem, K. M., & Shaaban, M. I. (2023). It is the time for quorum sensing inhibition as alternative strategy of antimicrobial therapy. *Cell Communication and Signaling*, 21(1), 1-14. <https://doi.org/10.1186/s12964-023-01154-9>
- Nasrollahian, S., Graham, J. P., & Halaji, M. (2024). A review of the mechanisms that confer antibiotic resistance in pathotypes of *E. coli*. *Frontiers in Cellular and Infection Microbiology*, 14. <https://doi.org/10.3389/fcimb.2024.1387497>
- Newman, D. J., & Cragg, G. M. (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. *Journal of natural products*, 75(3), 311-335. <https://doi.org/10.1021/np200906s>
- Newman, D. J., & Cragg, G. M. (2016). Natural products as sources of new drugs from 1981 to 2014. *Journal of natural products*, 79(3), 629-661. <https://doi.org/10.1021/acs.jnatprod.5b01055>
- Oakenfull, D., & Sidhu, G. S. (1990). Could saponins be a useful treatment for hypercholesterolaemia?. *European journal of clinical nutrition*, 44(1), 79-88.
- Odds, F. C. (2003). Synergy, antagonism, and what the checkerboard puts between them. *Journal of antimicrobial chemotherapy*, 52(1), 1. <https://doi.org/10.1093/jac/dkg301>
- Pancu, D. F., Scurtu, A., Macasoi, I. G., Marti, D., Mioc, M., Soica, C., ... & Dehelean, C. (2021). Antibiotics: conventional therapy and natural compounds with antibacterial activity—a pharmaco-toxicological screening. *Antibiotics*, 10(4), 401. <https://doi.org/10.3390/antibiotics10040401>
- Paul, R. (2018). State of the globe: Rising antimicrobial resistance of pathogens in urinary tract infection. *Journal of global infectious diseases*, 10(3), 117-118. [https://doi.org/10.4103/jgid.jgid\\_104\\_17](https://doi.org/10.4103/jgid.jgid_104_17)
- Pirintzos, S., Panagiotopoulos, A., Bariotakis, M., Daskalakis, V., Lionis, C., Sourvinos, G., ... & Castanas, E. (2022). From traditional ethnopharmacology to modern natural drug discovery: A methodology discussion and specific examples. *Molecules*, 27(13), 4060. <https://doi.org/10.3390/molecules27134060>
- Pirintzos, S., Panagiotopoulos, A., Bariotakis, M., Daskalakis, V., Lionis, C., Sourvinos, G., ... & Castanas, E. (2022). From traditional ethnopharmacology to modern natural drug discovery: A methodology discussion and specific examples. *Molecules*, 27(13), 4060. <https://doi.org/10.3390/molecules27134060>
- Plaper, A., Golob, M., Hafner, I., Oblak, M., Šolmajer, T., & Jerala, R. (2003). Characterization of quercetin binding site on DNA gyrase. *Biochemical and biophysical research communications*, 306(2), 530-536. [https://doi.org/10.1016/s0006-291x\(03\)01006-4](https://doi.org/10.1016/s0006-291x(03)01006-4)
- Pole, S. (2006). *Ayurvedic medicine: the principles of traditional practice*. Elsevier Health Sciences.
- Pothoven, R. (2023). Management of urinary tract infections in the era of antimicrobial resistance. *Drug Target Insights*, 17, 126-137. <https://doi.org/10.33393/dti.2023.2660>
- Prassas, I., & Diamandis, E. P. (2008). Novel therapeutic applications of cardiac glycosides. *Nature reviews Drug discovery*, 7(11), 926-935. <https://doi.org/10.1038/nrd2682>
- Ralte, L., Sailo, H., & Singh, Y. T. (2024). Ethnobotanical study of medicinal plants used by the indigenous community of the western region of Mizoram, India. *Journal of Ethnobiology and Ethnomedicine*, 20(1), 2. <https://doi.org/10.1186/s13002-023-00642-z>
- Rudrappa, T., & Bais, H. P. (2008). Curcumin, a known phenolic from *Curcuma longa*, attenuates the virulence of *Pseudomonas aeruginosa* PAO1 in whole plant and animal pathogenicity models. *Journal of agricultural and food chemistry*, 56(6), 1955-1962. <https://doi.org/10.1021/jf072591j>
- Saper, R. B., Kales, S. N., Paquin, J., Burns, M. J., Eisenberg, D. M., Davis, R. B., & Phillips, R. S. (2004). Heavy metal content of ayurvedic herbal medicine products. *Jama*, 292(23), 2868-2873. <https://doi.org/10.1001/jama.292.23.2868>

- Schippmann, U., Leaman, D. J., & Cunningham, A. B. (2002). Impact of cultivation and gathering of medicinal plants on biodiversity: global trends and issues. *Biodiversity and the ecosystem approach in agriculture, forestry and fisheries*.
- Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi J Biol Sci*. 2015 Jan;22(1):90-101. <https://doi.org/10.1016/j.sjbs.2014.08.002>
- Shariati, A., Noei, M., Askarinia, M., Khoshbayan, A., Farahani, A., & Chegini, Z. (2024). Inhibitory effect of natural compounds on quorum sensing system in *Pseudomonas aeruginosa*: a helpful promise for managing biofilm community. *Frontiers in Pharmacology*, 15. <https://doi.org/10.3389/fphar.2024.1350391>
- Siddiqui, S. A., Erol, Z., Rugji, J., Taşçı, F., Kahraman, H. A., Toppi, V., ... & Castro-Muñoz, R. (2023). An overview of fermentation in the food industry-looking back from a new perspective. *Bioresources and Bioprocessing*, 10(1), 85. <https://doi.org/10.1186/s40643-023-00702-y>
- Skindersoe, M. E., Ettinger-Epstein, P., Rasmussen, T. B., Bjarnsholt, T., de Nys, R., & Givskov, M. (2008). Quorum sensing antagonism from marine organisms. *Marine Biotechnology*, 10, 56-63. <https://doi.org/10.1007/s10126-007-9036-y>
- Tandogdu, Z., & Wagenlehner, F. M. (2016). Global epidemiology of urinary tract infections. *Current Opinion in Infectious Diseases*, 29(1), 73-79. <https://doi.org/10.1097/QCO.0000000000000228>
- Tipper D. J. (1985). Mode of action of beta-lactam antibiotics. *Pharmacology & therapeutics*, 27(1), 1–35. [https://doi.org/10.1016/0163-7258\(85\)90062-2](https://doi.org/10.1016/0163-7258(85)90062-2)
- Tu, Y. (2011). The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. *Nature medicine*, 17(10), 1217-1220. <https://doi.org/10.1038/nm.2471>
- Vaou, N., Stavropoulou, E., Voidarou, C., Tsakris, Z., Rozos, G., Tsigalou, C., & Bezirtzoglou, E. (2022). Interactions between medical plant-derived bioactive compounds: focus on antimicrobial combination effects. *Antibiotics*, 11(8), 1014. <https://doi.org/10.3390/antibiotics11081014>
- Vattem, D. A., Mihalik, K., Crixell, S. H., & McLean, R. J. (2007). Dietary phytochemicals as quorum sensing inhibitors. *Fitoterapia*, 78(4), 302-310. <https://doi.org/10.1016/j.fitote.2007.03.009>
- Watve, M. G., Tickoo, R., Jog, M. M., & Bhole, B. D. (2001). How many antibiotics are produced by the genus *Streptomyces*?. *Archives of microbiology*, 176, 386-390. <https://doi.org/10.1007/s002030100345>
- Williamson, E. M. (2001). Synergy and other interactions in phytomedicines. *Phytomedicine*, 8(5), 401-409. <https://doi.org/10.1078/0944-7113-00060>
- Wood, J. N. (2015). From plant extract to molecular panacea: a commentary on Stone (1763)'An account of the success of the bark of the willow in the cure of the agues'. *Philosophical Transactions of the Royal Society B: Biological Sciences*, 370(1666), 20140317. <https://doi.org/10.1098/rstb.2014.0317>
- World Health Organization. (2014). *Antimicrobial resistance: global report on surveillance*. World Health Organization.
- Wright, G. D. (2005). Bacterial resistance to antibiotics: enzymatic degradation and modification. *Advanced drug delivery reviews*, 57(10), 1451-1470. <https://doi.org/10.1016/j.addr.2005.04.002>
- Wright, G. D. (2016). Antibiotic adjuvants: rescuing antibiotics from resistance. *Trends in microbiology*, 24(11), 862-871. <https://doi.org/10.1016/j.tim.2016.06.009>